Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 41Genitourinary 25Thoracic 20Gynecologic 15Lymphoid 11Head & Neck 10Breast 9Sarcoma 5Other solid neoplasm 2Dermatologic 2Tumor-Agnostic 1Other hematologic neoplasm 1CNS 1

Conditions

Pancreatic Neoplasms 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumour 1

Interventions

pembrolizumab 15Injections 13Pemetrexed 8Carboplatin 8tislelizumab 6Interviews as Topic 6Standard of Care 5Specimen Handling 5Practice Guidelines as Topic 5Fluorouracil 5Cisplatin 5Bevacizumab 5atezolizumab 4Oxaliplatin 4Docetaxel 4sotorasib 3fludarabine 3Paclitaxel 3Nivolumab 3Methods 3Leucovorin 3Irinotecan 3Educational Status 3Early Intervention, Educational 3Capecitabine 3toripalimab 2Radiotherapy, Intensity-Modulated 2Patient Navigation 2Magnetic Resonance Spectroscopy 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gemcitabine × Other solid neoplasm × 30 days × Clear all
NCT07111546 2026-05-26

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Nanjing Leads Biolabs Co.,Ltd

Phase 2 Recruiting
140 enrolled
Other solid neoplasm

Advanced Solid Tumour

NCT07563738 2026-05-04

TEADCO

Orion Corporation, Orion Pharma

Phase 1/2 Recruiting
229 enrolled
GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡